Amytrx Therapeutics announced it raised $725,000 in an initial filing from an offering of $6 Million

Company

Location

About

Amytrx is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world's most debilitating diseases.